News & Updates

Individuals living with advanced HIV infection who received pemivibart demonstrate good tolerability, with no cases of RT-PCR-confirmed symptomatic COVID-19 reported through month 6, as shown by the results of a subgroup analysis of the CANOPY study.

Several infants born to mothers living with HIV die within 50 weeks, and some of the factors that may contribute to infant death include lower maternal CD4 count, higher viral load, and maternal antiretroviral (ART) regimen, among others, suggests a study presented at CROI 2026.

In patients with muscle-invasive bladder cancer (MIBC) eligible for cisplatin-based chemotherapy, neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab elicits improvements in event-free survival (EFS), overall survival (OS), and pathological complete response (pCR) rate relative to neoadjuvant gemcitabine plus cisplatin, according to the phase III KEYNOTE-B15 study.

Sequential transarterial chemoembolization, stereotactic body radiotherapy, and immunotherapy (START-FIT) using the STRIDE regimen of single-dose tremelimumab plus regular-interval durvalumab offers promising efficacy and is well tolerated in patients with locally advanced, unresectable hepatocellular carcinoma (HCC), a single-arm, multicentre, phase II study in Hong Kong has shown.